Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Addex Therapeutics (ADXN) Receivables - Other (2018 - 2024)

Addex Therapeutics' Receivables - Other history spans 5 years, with the latest figure at $9094.5 for Q4 2024.

  • On a quarterly basis, Receivables - Other fell 80.28% to $9094.5 in Q4 2024 year-over-year; TTM through Dec 2024 was $9094.5, a 80.28% decrease, with the full-year FY2024 number at $9094.5, down 80.28% from a year prior.
  • Receivables - Other came in at $9094.5 for Q4 2024, down from $42130.9 in the prior quarter.
  • The five-year high for Receivables - Other was $1.2 million in Q2 2021, with the low at $9094.5 in Q4 2024.
  • Historically, Receivables - Other has averaged $205906.4 across 4 years, with a median of $124607.0 in 2024.
  • Biggest five-year swings in Receivables - Other: crashed 93.27% in 2022 and later soared 237.59% in 2023.
  • Year by year, Receivables - Other stood at $140985.3 in 2021, then dropped by 11.65% to $124562.6 in 2022, then plummeted by 62.98% to $46116.7 in 2023, then tumbled by 80.28% to $9094.5 in 2024.
  • Business Quant data shows Receivables - Other for ADXN at $9094.5 in Q4 2024, $42130.9 in Q3 2024, and $33748.8 in Q2 2024.